Carlos L. Arteaga, M.D., professor of Medicine and Cancer Biology and associate director for Clinical Research at Vanderbilt-Ingram Cancer Center (VICC), has been named one of the winners of this year’s Susan G. Komen for the Cure Brinker Awards for Scientific Distinction. The Brinker Awards for Scientific Distinction were established in 1992 to recognize the efforts of [...]
News: HER2-positive breast cancer
Dr. Carlos Arteaga, director of the Vanderbilt-Ingram Cancer Center’s breast cancer program, describes how advances in personalized cancer medicine contributes to breast cancer treatment.
Combining targeted therapies might be required for maximum anti-tumor activity when treating HER2-positive breast cancers, according to two new studies by Vanderbilt-Ingram Cancer Center (VICC) investigators. The findings, reported in two papers in the Proceedings of the National Academy of Sciences (PNAS), suggest that upregulation of the HER3 receptor limits the effectiveness of two classes [...]